2 registrations that name yohimbine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
Not yet recruitingNCT04231708
Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder
Phase 2
Wayne State University
About 20 people
Starts Oct 2026 (estimated)
In plain words A Phase 2 study of yohimbine in people 21 to 60, run by Wayne State University. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 60. Conditions: Opioid Use Disorder.
Meet DSM-5 criteria for OUD;
Age 21-60 yr;
Right handed;
Males and non-pregnant/non-lactating females;
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Yohimbine + Hydrocortisone; Active rTMS; Placebo; Sham rTMS
Registered summary
This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07817030
Evaluation of Solanidine as an Exogenous Biomarker to Phenotype CYP2D6 Activity in Humans
No phase
University Medicine Greifswald
About 30 people
Starts Sep 21, 2026 (estimated)
In plain words A study of yohimbine in people 18 to 40, run by University Medicine Greifswald. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40; healthy volunteers accepted. Conditions: Pharmacokinetic Study in Healthy Volunteers.
individuals of both biological sexes, assigned as women or men at birth
age: ≥ 18 and ≤ 40 years
possesses the ability to understand the study purpose and design
contractually capable and provides signed informed consent form
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Yohimbine; Consumption of a defined potato-rich meal
Registered summary
This study investigates the evaluation of solanidine as an exogenous biomarker to phenotype CYP2D6-activity in humans. Participants will be classified by their CYP2D6 genotype into poor metabolizers (PM), low intermediate metabolizers (LIM), extensive metabolizers (EM) and ultra-rapid metabolizers (UM), forming four distinct study arms: Arm 1) Poor Metabolizers (PM) n=10 Arm 2) Low Intermediate Metabolizers (LIM) n=5 Arm 3) Extensive Metabolizers (EM) n=10 Arm 4) Ultra-rapid Metabolizers (UM) n=5 Participants will be given a standardized potato-rich meal, serving as the natural source of… The full summary is on the listing.